Novo wins EU recommendation for two-in-one diabetes drug

[riky]

Novo wins EU recommendation for two-in-one diabetes drug

<p><a href="http://news.yahoo.com/novo-sees-two-one-diabetes-drug-europe-first-114128864--finance.html"><img src="http://l3.yimg.com/bt/api/res/1.2/Hj304fHruCttwrNujqo7Qw--/YXBwaWQ9eW5ld3M7Zmk9ZmlsbDtoPTg2O3E9NzU7dz0xMzA-/http://media.zenfs.com/en_us/News/Reuters/2014-07-25T114128Z_1_LYNXMPEA6O0JN_RTROPTP_2_OBESITY-BUSINESS.JPG" width="130" height="86" alt="Insulin jabs are pictured on a production line in Novo Nordisk's plant in Kalundborg" align="left" title="Insulin jabs are pictured on a production line in Novo Nordisk's plant in Kalundborg" border="0" /></a>By Ben Hirschler LONDON (Reuters) - A Novo Nordisk drug combining its long-acting insulin degludec with its type 2 diabetes treatment Victoza has been recommended for approval in Europe, in an important boost for the Danish company. The European Medicines Agency said on Friday it had issued a positive opinion for Xultophy, previously known as IDegLira, implying the medicine is likely to be formally approved by the European Commission within three months. Novo said it planned to launch Xultophy in the first European markets in the first half of 2015. Jakob Riis, executive vice president of marketing and medical affairs at Novo Nordisk, said Britain, Germany and Denmark were likely to be among the first launch markets for the product.</p><br clear="all"/>

Source: You are not allowed to view links. Register or Login